A Universal Strategy for Evaluation and Quantification of Potential Genotoxic Impurities of Hydrazine Derivatives in Isoniazid Injection
Authors:
- 31 July 2025
- journal article
- Published by Wiley in Journal of Separation Science
- Vol. 48 (8) , e70235
Abstract
Isoniazid is an irreplaceable first‐line anti‐tuberculosis drug. Its synthesis requires hydrazine as a starting material, which is classified as a Class 2 genotoxic impurity according to the ICH M7 guideline. Consequently, there is a risk of introducing potential genotoxic impurities (PGIs) containing hydrazine‐related alerting structural during production. This study employed a systematic approach to assess the risks of PGIs in isoniazid and developed a novel LC‐MS/MS method for accurate control and quantification of these impurities. First, candidate impurities were preliminarily predicted using quantitative structure–activity relationship (QSAR) systems based on expert rule and statistics. Subsequently, acceptable impurity limits were established based on the prediction results. Finally, an LC‐MS/MS method was developed to quantify the selected PGIs. The results indicated that the impurities were classified as Class 3 (3,5‐bis(4‐pyridyl)‐4‐amino‐1,2,4‐triazole), Class 4 (benzohydrazide, picolinohydrazide, and nicotinohydrazide), and Class 5 (3,6‐di(4‐pyridyl)‐1,4‐dihydro‐1,2,4,5‐tetrazine). According to the ICH Q3B guidelines and the threshold of toxicological concern (TTC) based on the duration of administration, the limits of Class 4 and 5 impurities were set at 0.1%, and the limit of Class 3 impurities was set at 0.0066%. The established method demonstrated excellent linearity ( r > 0.999) within the range of 0.2‐25 ng/mL. And good recoveries were observed in the range of 88.1%–113.0%. The method was successfully applied to quantify impurities in 77 batches of isoniazid injections, all of which complied with the established acceptance limits. This universal strategy enhances quality control of isoniazid formulations, ensuring clinical safety through robust impurity assessment and validated analytical methodology.Keywords
Funding Information
- Shenzhen Science and Technology Innovation Program (JCYJ20230807112702005)
This publication has 27 references indexed in Scilit:
- Microextraction by packed sorbent of N‐nitrosamines from Losartan tablets using a high‐throughput robot platform followed by liquid chromatography‐tandem mass spectrometryJournal of Separation Science, 2023
- Ultra‐high‐speed liquid chromatography combined with mass spectrometry detection analytical methods for the determination of nitrosamine drug substance‐related impuritiesJournal of Separation Science, 2023
- Method for trace determination of N‐nitrosamines impurities in metronidazole benzoate using high‐performance liquid chromatography coupled with atmospheric‐pressure chemical ionization tandem mass spectrometryJournal of Separation Science, 2022
- Development and validation of LC–QTOF–MS/MS method for the identification and determination of low levels of a genotoxic impurity, 4,6‐dichloro‐5‐nitro‐2‐(propylthio)pyrimidine in ticagrelor APIBiomedical Chromatography, 2022
- Development and validation of an analytical method for quantitative determination of three potentially genotoxic impurities in vildagliptin drug material using HPLC‐MSJournal of Separation Science, 2021
- Identification, isolation, characterization, and UHPLC quantification of potential genotoxic impurities in linagliptinJournal of Separation Science, 2018
- Simultaneous quantitation of trace level hydrazine and acetohydrazide in pharmaceuticals by benzaldehyde derivatization with sample ‘matrix matching’ followed by liquid chromatography–mass spectrometryJournal of Chromatography A, 2016
- LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay methodJournal of Pharmaceutical and Biomedical Analysis, 2007
- Classification according to chemical structure, mutagenicity to Salmonella and level of carcinogenicity of a further 42 chemicals tested for carcinogenicity by the U.S. National Toxicology ProgramMutation Research/Genetic Toxicology, 1989
- Synthesis of isoniazid from 4-cyanopyridinePharmaceutical Chemistry Journal, 1972